DZDerek J. Zangerle

Derek J. Zangerle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Derek J. Zangerle has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inducible Laryngeal Obstruction in Hypermobile Patients

    by Stacey M. Menton, DeLisa Fairweather, Frances C. Wilson, Derek J. Zangerle, Emma F. Murphy, Ashley A. Darakjian, Chandler C. Thompson, Shilpa N. Gajarawala, Dacre R. T. Knight, Katelyn A. Bruno, et al.

    Objective: To determine whether patients with hypermobile Ehlers‐Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD) and inducible laryngeal obstruction (ILO) have more voice, cough, swallowing, GI issues, and MC activation than patients without ILO. Methods: This retrospective study of 2162 patients meeting 2017 diagnostic criteria for hEDS ( n = 507) or HSD ( n = 1655) who were seen at the EDS Clinic in Mayo Clinic Florida from November 2019 to June 2025 compared patients who screened positive for ILO to those who screened negative. Patients were examined for self‐reported symptoms of voice, cough, swallow, and GI issues as well as MC activation. Results: Among patients with hEDS or HSD, 23.1% and 17.1% respectively screened positive for ILO. Patients with ILO had significantly more voice, cough, and swallow issues than patients without ILO (all p ≤ 0.007). Both diagnoses had more gastroesophageal reflux disease (GERD) (hEDS: 55.6% vs. 40.9%, p = 0.004; HSD: 55.8% vs. 42.2%, p < 0.0001). Additionally, both hEDS and HSD patients with ILO self‐reported 18 allergy‐related symptoms more often than those without ILO and had higher MC scores indicating widespread MC activation (all p < 0.0001). Cough, dysphagia, and elevated MC score were statistically significant predictors of ILO in both hEDS and HSD within a logistic regression analysis. Conclusions: Chronic cough, dysphagia, and elevated MC symptom burden were the strongest independent predictors of ILO across both hEDS and HSD, underscoring the need for routine multidisciplinary laryngeal assessment in this population. Level of Evidence: 3.

  • Open Access

    Mast cell score associates with wide-spread mast cell symptoms and comorbidities in patients with hEDS and HSD

    by Frances C. Wilson, Derek J. Zangerle, Lincoln E. Rozen, Jessica J. Fliess, Ashley A. Darakjian, Keith A. Sacco, Charwan Hamilton, Max W. Strandes, Alayna M. Puls, Cameron J. Hartmoyer, et al.

    Background: Wide-spread mast cell (MC)-associated symptoms and MC activation syndrome (MCAS) are often reported in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). The goal of this study was to develop a novel MC score based on 11 self-reported MC-related conditions with clinical and research utility to better understand MC symptoms in hEDS and HSD patients. Methods: From November 1, 2019, to June 13, 2025, patients ( n =2,141) filled out an Intake Questionnaire at the Mayo Clinic Florida EDS Clinic that included 11 self-reported questions related to categories of MC-related conditions for a MC score ranging from 0/11 to 11/11. Based on the MC score distribution in hEDS and HSD patients, a MC score of 0-1 was considered a low MC score and ≥5 was considered a high MC score. Symptoms/comorbidities were compared between patients with high vs. low MC scores. Results: From the 2,141 hEDS/HSD patients, 535 (25.0%) had a MC score ≥5 (Hi MC). MCAS-specific symptoms such as nausea and vomiting were reported more often in hEDS/HSD patients with a high vs. low MC score ( p n =50/group), although high MC scores were found to significantly reduce urinary creatinine levels indicating that the protein used to normalize data was affected by MC activity. In contrast, random blood IgE, tryptase and major basic protein (MBP) by ELISA were increased in patients with high MC scores (e.g., IgE hEDS p =0.0004, HSD p =0.003). Of note, the percentage of patients reporting abuse or post-traumatic stress disorder was nearly doubled in patients with high vs. low MC scores (Abuse and PTSD: hEDS p < 0.0001; HSD p < 0.0001). Overall, 109/135 (80.7%) in hEDS and 129/135 (95.6%) in HSD reported more symptoms/comorbidities if they had a high MC score. Conclusions: We found that hEDS/HSD patients with high MC scores self-reported more widespread symptoms/comorbidities and higher MC-related blood markers than patients with low MC scores indicating the utility of this tool to evaluate the level of widespread MC activity in hEDS, HSD and other patients.